News | July 22, 2023
Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Subscribe To Our Newsletter & Stay Updated
